Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS).

World J Urol 2015 Nov 31;33(11):1735-40. Epub 2015 Mar 31.

Department of Urology, Peijas Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 900, 00029, Helsinki, Finland.

Purpose: To evaluate the utility of percentage of free serum PSA (%fPSA) as a predictor of adverse rebiopsy findings, treatment change and radical prostatectomy (RP) findings in a prospective active surveillance (AS) trial.

Methods: Patients enrolled in the global PRIAS study with baseline %fPSA available were included. Putative baseline predictors (e.g. PSA, %fPSA) of adverse rebiopsy findings were explored using logistic regression analysis. Association of variables with treatment change and RP findings over time were evaluated with Cox regression analysis. Active treatment-free survival was assessed with a Kaplan-Meier method.

Results: Of 3701 patients recruited to PRIAS, 939 had %fPSA measured at study entry. Four hundred and thirty-eight of them had %fPSA available after 1 year. Median follow-up was 17.2 months. First rebiopsy results were available for 595 patients and of those, 144 (24.2 %) had adverse findings. A total of 283 (30.1 %) patients discontinued surveillance, of those 181 (64.0 %) due to protocol-based reasons. Although median %fPSA values were significantly lower in patients who changed treatment, according to the multivariate regression analysis, initial %fPSA value was not predictive for treatment change or adverse rebiopsy findings. However, the probability of discontinuing AS was significantly lower in patients with "favourable" initial %fPSA characteristics and %fPSA during follow-up (initial %fPSA ≥15 and positive %fPSA velocity) compared to those with "adverse" %fPSA characteristics (initial %fPSA <15 and negative %fPSA velocity).

Conclusions: Diagnostic %fPSA provides no additional prognostic value when compared to other predictors already in use in AS protocols. However, %fPSA velocity during surveillance may aid in predicting the probability for future treatment change.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-015-1542-3DOI Listing
November 2015
3 Reads

Publication Analysis

Top Keywords

initial %fpsa
16
%fpsa
13
rebiopsy findings
12
adverse rebiopsy
12
regression analysis
12
treatment change
12
active surveillance
8
%fpsa characteristics
8
psa %fpsa
8
lower patients
8
prospective active
8
findings
6
patients
6
cox regression
4
analysis active
4
"favourable" initial
4
evaluated cox
4
explored logistic
4
findings explored
4
144 242
4

References

(Supplied by CrossRef)

MR Cooperberg et al.
J Urol 2007

C Parker et al.
Lancet Oncol 2004

M Bul et al.
Eur Urol 2013

MA Dall’Era et al.
Cancer 2008

NJ As van et al.
Eur Urol 2008

L Klotz et al.
J Clin Oncol 2010

JJ Tosoian et al.
J Clin Oncol 2011

A Ouzzane et al.
Curr Opin Urol 2012

L Stamatakis et al.
Cancer 2013

S Isharwal et al.
Urology 2011

WJ Catalona et al.
JAMA 1995

Similar Publications